VCYT
Veracyte, Inc.NASDAQ
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Tue, Nov. 29, 1:15 PM
    • Janney Capital upgrades molecular cytology firm Veracyte (VCYT +3.9%) to Buy from Neutral.
    • The company's lead tests are Afirma for assessing thyroid nodules and Percepta for lung cancer diagnosis.
    | Tue, Nov. 29, 1:15 PM
  • Mon, Nov. 21, 4:46 PM
    • Veracyte (NASDAQ:VCYT) appoints Keith Kennedy as Chief Financial Officer effective December 6. He joins the firm from MCG Capital where he was President & CEO.
    | Mon, Nov. 21, 4:46 PM
  • Thu, Nov. 3, 4:14 PM
    • Veracyte (NASDAQ:VCYT): Q3 EPS of -$0.20 beats by $0.16.
    • Revenue of $18.6M (+50.7% Y/Y) beats by $1.88M.
    • Press Release
    | Thu, Nov. 3, 4:14 PM
  • Wed, Nov. 2, 8:27 AM
    • Veracyte (NASDAQ:VCYT) prices its public offering of 5M shares of common stock at $6. Underwriters over-allotment is an additional 750K shares. Closing date is November 7. Net proceeds will fund working capital and general corporate purposes.
    • Yesterday's close was $7.13.
    | Wed, Nov. 2, 8:27 AM
  • Mon, Oct. 17, 5:47 PM
    • Veracyte (NASDAQ:VCYT): expects Q3 EPS in the range of ($0.20) - ($0.21) vs. a consensus of ($0.39).
    • Revenue is expected to be $18.6M (+51% Y/Y). This includes an estimated $3.5M increase due to the accrual of tests that would have previously been recognized upon cash receipt.
    • Press Release
    | Mon, Oct. 17, 5:47 PM
  • Thu, Sep. 8, 11:00 AM
    | Thu, Sep. 8, 11:00 AM
  • Wed, Aug. 3, 4:29 PM
    • Veracyte (NASDAQ:VCYT): Q2 EPS of -$0.40 misses by $0.07.
    • Revenue of $14.68M (+23.3% Y/Y) misses by $0.13M.
    • Press Release
    | Wed, Aug. 3, 4:29 PM
  • Mon, Jun. 13, 4:47 PM
    • Veracyte (NASDAQ:VCYT) Chief Financial Officer Shelly Guyer has informed the company of her intention to resign to pursue other opportunities. She will remain with the firm during a transition period. A search for a successor has been initiated.
    | Mon, Jun. 13, 4:47 PM
  • Thu, May 5, 4:59 PM
    • Veracyte (NASDAQ:VCYT): Q1 EPS of -$0.36 misses by $0.01.
    • Revenue of $13.55M (+20.8% Y/Y) beats by $0.47M.
    | Thu, May 5, 4:59 PM
  • Thu, Mar. 10, 4:13 PM
    • Veracyte (NASDAQ:VCYT): Q4 EPS of -$0.29 beats by $0.01.
    • Revenue of $14M (+14.8% Y/Y) misses by $0.45M.
    | Thu, Mar. 10, 4:13 PM
  • Nov. 18, 2015, 12:47 PM
    | Nov. 18, 2015, 12:47 PM | 9 Comments
  • Nov. 18, 2015, 11:45 AM
    • Thinly traded micro cap Veracyte (VCYT +19%) jumps on a 5x surge in volume, albeit on turnover of less than 400K shares, in response to its announcement that the reimbursement rate set by the Centers for Medicare and Medicaid Services (CMS) for its Afirma GEC test will be remain at $3,200 for 2016 while the gapfill process runs its course. The revised price, if changed, will go into effect on January 1, 2017.
    • CMS's decision to use a gapfill approach to pricing is bullish for the company since it will allow a higher price than its previously-planned "crosswalk" which pegged the product to other less-expensive tests. CMS uses a gapfill process for tests that have no comparables. In the first year, pricing is determined based on what carriers actually pay which serves as the basis for the formal reimbursed amount for the second year, determined by the median price paid by the carriers in year one.
    • Afirma GEC (Gene Expression Classifier) is a test, offered as a service, that helps doctors reduce the number of avoidable thyroid surgeries by preoperatively identifying benign nodules among those that were originally classified by cytopathology as indeterminate. It combines cytopathology (microscopic examination of the cells) with genomic testing. If the cytopathology diagnosis is benign or malignant, the analysis is complete. The GEC is used only when the cytopathology diagnosis is indeterminate.
    | Nov. 18, 2015, 11:45 AM
  • Nov. 5, 2015, 4:48 PM
    • Veracyte (NASDAQ:VCYT): Q3 EPS of -$0.32 beats by $0.01.
    • Revenue of $12.3M (+25.0% Y/Y) misses by $0.42M.
    | Nov. 5, 2015, 4:48 PM
  • Aug. 13, 2015, 4:13 PM
    • Veracyte (NASDAQ:VCYT): Q2 EPS of -$0.35 misses by $0.04.
    • Revenue of $11.9M (+37.1% Y/Y) misses by $0.33M.
    • Shares +2.6%.
    | Aug. 13, 2015, 4:13 PM
  • Jun. 26, 2015, 12:45 PM
    | Jun. 26, 2015, 12:45 PM
  • May 14, 2015, 4:09 PM
    • Veracyte (NASDAQ:VCYT): Q1 EPS of -$0.34 beats by $0.03.
    • Revenue of $11.2M (+49.3% Y/Y)
    | May 14, 2015, 4:09 PM